JP2013501722A - 前立腺癌の処置 - Google Patents

前立腺癌の処置 Download PDF

Info

Publication number
JP2013501722A
JP2013501722A JP2012523949A JP2012523949A JP2013501722A JP 2013501722 A JP2013501722 A JP 2013501722A JP 2012523949 A JP2012523949 A JP 2012523949A JP 2012523949 A JP2012523949 A JP 2012523949A JP 2013501722 A JP2013501722 A JP 2013501722A
Authority
JP
Japan
Prior art keywords
compound
administration
composition
subject
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012523949A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013501722A5 (enExample
Inventor
モリソン，ジョディー，ポープ
スタイン，サイ，アーロン
ケースビアー，デイビッド，スコット
Original Assignee
トーカイ ファーマシューティカルズ，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トーカイ ファーマシューティカルズ，インク． filed Critical トーカイ ファーマシューティカルズ，インク．
Publication of JP2013501722A publication Critical patent/JP2013501722A/ja
Publication of JP2013501722A5 publication Critical patent/JP2013501722A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Reproductive Health (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
JP2012523949A 2009-08-07 2010-08-05 前立腺癌の処置 Pending JP2013501722A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23225709P 2009-08-07 2009-08-07
US61/232,257 2009-08-07
US26126509P 2009-11-13 2009-11-13
US61/261,265 2009-11-13
PCT/US2010/044570 WO2011017534A2 (en) 2009-08-07 2010-08-05 Treatment of prostate cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015221564A Division JP2016074687A (ja) 2009-08-07 2015-11-11 前立腺癌の処置

Publications (2)

Publication Number Publication Date
JP2013501722A true JP2013501722A (ja) 2013-01-17
JP2013501722A5 JP2013501722A5 (enExample) 2013-09-19

Family

ID=43535282

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012523949A Pending JP2013501722A (ja) 2009-08-07 2010-08-05 前立腺癌の処置
JP2015221564A Pending JP2016074687A (ja) 2009-08-07 2015-11-11 前立腺癌の処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015221564A Pending JP2016074687A (ja) 2009-08-07 2015-11-11 前立腺癌の処置

Country Status (8)

Country Link
US (5) US8791094B2 (enExample)
EP (1) EP2461814A4 (enExample)
JP (2) JP2013501722A (enExample)
KR (1) KR20120056267A (enExample)
AU (1) AU2010279398A1 (enExample)
BR (1) BR112012002797A2 (enExample)
CA (1) CA2770092A1 (enExample)
WO (1) WO2011017534A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100048524A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
WO2009129208A2 (en) * 2008-04-14 2009-10-22 University Of Maryland, Baltimore Compositions and methods of inducing endoplasmic reticulum stress reponse
EP2393827B1 (en) 2009-02-05 2015-10-07 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
PE20121048A1 (es) 2009-06-26 2012-08-25 Novartis Ag Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
EP2461814A4 (en) 2009-08-07 2012-12-05 Tokai Pharmaceuticals Inc PROSTATE CANCER TREATMENT
MX359399B (es) 2011-04-28 2018-09-27 Novartis Ag Inhibidores de 17alfa-hidroxilasa/c17-20-liasa.
JP2014523445A (ja) * 2011-07-18 2014-09-11 トーカイ ファーマシューティカルズ，インク． 前立腺癌を処置するための新規な組成物及び方法
US20130203615A1 (en) * 2011-08-05 2013-08-08 Gen-Probe Incorporated Antiandrogen therapy monitoring methods and compositions
WO2013071177A1 (en) * 2011-11-10 2013-05-16 Tokai Pharmaceuticals, Inc. Methods and compositions for inhibition of androgen receptor activity
CA2904170A1 (en) 2013-03-14 2014-09-25 University Of Maryland, Baltimore Androgen receptor down-regulating agents and uses thereof
KR20160058774A (ko) 2013-08-12 2016-05-25 토카이 파마슈티컬, 아이엔씨. 안드로겐-표적 치료제를 이용하는 종양 질환 치료를 위한 바이오마커
WO2015170336A1 (en) 2014-05-09 2015-11-12 Council Of Scientific & Industrial Research 16α-HETEROARYL PREGNENOLONE ACETATE AND A PROCESS FOR PREPARATION THEREOF
WO2016119742A1 (zh) * 2015-01-29 2016-08-04 苏州晶云药物科技有限公司 (3β)-17-(1H-苯并咪唑-1-基)雄甾-5，16-二烯-3-醇的盐及其制备方法
ITUA20164043A1 (it) * 2016-06-01 2017-12-01 Ind Chimica Srl Processo per la preparazione di 3β-idrossi-17-(1H-benzimidazol-1-il)androsta-5,16-diene
WO2017208132A1 (en) * 2016-06-01 2017-12-07 Industriale Chimica S.R.L. Process for the preparation of galeterone
US11756656B2 (en) * 2018-06-14 2023-09-12 Astrazeneca Uk Limited Methods for treating and preventing symptoms of asthma with a corticosteroid pharmaceutical composition
US12337004B2 (en) * 2019-04-27 2025-06-24 Health Research, Inc. Coumarin-modified androgens for the treatment of prostate cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008536807A (ja) * 2005-03-02 2008-09-11 ユニバーシティ、オブ、メリーランド 新規なｃ−１７−ヘテロアリールステロイドｃｙｐ１７阻害剤／抗アンドロゲン：合成、インビトロ生物活性、薬物動態および抗腫瘍活性

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH621803A5 (enExample) * 1974-08-08 1981-02-27 Siphar Sa
US5604213A (en) * 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
NZ266640A (en) * 1993-04-30 1998-01-26 Pacific Northwest Research Fou Diagnosing genotoxic or carcinogenic status by analysing cellular redox potential where increased risk is indicated when the potential favours oxidatively derived modified nucleotides
US5994335A (en) * 1997-10-17 1999-11-30 The University Of Maryland, Baltimore 17-azolyl steroids useful as androgen synthesis inhibitors
US20030054053A1 (en) * 2001-09-20 2003-03-20 Charles Young Methods and compositions for inhibiting the proliferation of prostate cancer cells
PT1660115E (pt) 2003-07-29 2011-08-24 Dompe Spa ASSOCIAÇÃO FARMACjUTICA DE G-CSF E DE PLGF ÚTIL NA MOBILIZAÇÃO DE CÉLULAS ESTAMINAIS DO SANGUE
JP4585201B2 (ja) * 2004-01-23 2010-11-24 丸善製薬株式会社 アンドロゲン受容体結合阻害剤、養毛剤、皮脂分泌抑制剤及び前立腺肥大抑制剤
WO2008154382A1 (en) * 2007-06-06 2008-12-18 University Of Maryland, Baltimore Hdac inhibitors and hormone targeted drugs for the treatment of cancer
US20100048524A1 (en) * 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
EP2461814A4 (en) 2009-08-07 2012-12-05 Tokai Pharmaceuticals Inc PROSTATE CANCER TREATMENT

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008536807A (ja) * 2005-03-02 2008-09-11 ユニバーシティ、オブ、メリーランド 新規なｃ−１７−ヘテロアリールステロイドｃｙｐ１７阻害剤／抗アンドロゲン：合成、インビトロ生物活性、薬物動態および抗腫瘍活性

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6014031817; Ｔａｄａｓ　Ｖａｓａｉｔｉｓ，　ｅｔ　ａｌ．: 'Ａｎｄｒｏｇｅｎ　ｒｅｃｅｐｔｏｒ　ｉｎａｃｔｉｖａｔｉｏｎ　ｃｏｎｔｒｉｂｕｔｅｓ　ｔｏ　ａｎｔｉｔｕｍｏｒ　ｅｆｆｉｃａｃｙ　ｏｆ　１７｛ａｌｐｈａ｝-ｈｙｄｒｏｘｙｌａｓｅ／１７，２０-ｌｙａｓ' Ｍｏｌ　Ｃａｎｃｅｒ　Ｔｈｅｒ ７（８）, 2008, ２３４８-５７ *

Also Published As

Publication number Publication date
CA2770092A1 (en) 2011-02-10
US20170157148A1 (en) 2017-06-08
WO2011017534A2 (en) 2011-02-10
US9156878B2 (en) 2015-10-13
EP2461814A4 (en) 2012-12-05
US8791094B2 (en) 2014-07-29
WO2011017534A3 (en) 2011-06-30
US20150203528A1 (en) 2015-07-23
KR20120056267A (ko) 2012-06-01
US20110034428A1 (en) 2011-02-10
US20150166599A1 (en) 2015-06-18
AU2010279398A1 (en) 2012-03-08
JP2016074687A (ja) 2016-05-12
EP2461814A2 (en) 2012-06-13
BR112012002797A2 (pt) 2019-09-24
US20140343024A1 (en) 2014-11-20

Similar Documents

Publication Publication Date Title
JP2016074687A (ja) 前立腺癌の処置
US20160002283A1 (en) Novel compositions and methods for treating prostate cancer
TWI394571B (zh) 螺旋１２取向性之非類固醇抗雄激素及包含其之醫藥組合物、以及其等之用途
KR102606253B1 (ko) 2-(tert-부틸아미노)-4-((1r,3r,4r)-3-하이드록시-4-메틸사이클로헥실아미노)-피리미딘-5-카복사마이드의 제형
JP2001354590A (ja) 良性前立腺過形成の予防および／または治療のための組合せ療法
JP2004505061A (ja) うっ血性心不全の処置のための、エポキシ−ステロイド型アルドステロン拮抗薬とカルシウムチャンネル遮断薬の併用療法
JP2023522040A (ja) Ｎ末端ドメインアンドロゲン受容体阻害剤の固体形態およびその使用
KR20160058774A (ko) 안드로겐-표적 치료제를 이용하는 종양 질환 치료를 위한 바이오마커
JP2017535614A (ja) 疾患治療用の縮合二環式化合物
CN111479560A (zh) 用于治疗非转移性去势难治性前列腺癌的抗雄激素
US20140045938A1 (en) Substituted Phenyl Aziridine Precursor Analogs for Inhibiting Androgen-Independent Prostate Cancer Cell Growth
US20020123485A1 (en) Epoxy steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure
JP2004507495A (ja) 認知機能改善のためのアルドステロン受容体拮抗薬の使用
JP2002515484A (ja) ２−フェニルインドール化合物およびエストロゲン製剤からなる組成物
JP2012501334A (ja) 置換アミノチアゾール誘導体、医薬組成物、および使用の方法
JP2002543119A (ja) 環状尿素および環状アミド誘導体を用いた周期的管理
JP2002538172A (ja) 循環器疾患治療のためのアンギオテンシン変換酵素阻害薬およびエポキシ−ステロイドアルドステロン拮抗薬の組合せ療法
JP2020530026A (ja) 線維性疾患の治療における使用のための化合物及びその医薬組成物
JP2002543159A (ja) ベンズイミダゾロンとプロゲストゲンを含有する組成物
JP2022543679A (ja) 癌を処置する方法
US10799478B2 (en) Treatment of androgen deprivation therapy associated symptoms
JP2002543206A (ja) 環状尿素および環状アミド誘導体
HK1233508B (en) Treatment of androgen deprivation therapy associated symptoms
HK1233508A1 (en) Treatment of androgen deprivation therapy associated symptoms

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130716

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130716

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140730

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141017

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141024

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141126

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150104

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150713

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151111

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20151222

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20160129